Primer combination and kit for detecting POGZ gene pathogenic mutation

By providing primer sets and kits for POGZ gene pathogenic mutations, combined with Sanger sequencing or gel electrophoresis detection, the problems of high cost and long cycle of POGZ gene detection in the prior art are solved, and rapid and economical detection results are achieved .

CN118957055APending Publication Date: 2024-11-15SHENZHEN CITY BAOAN DISTRICT MATERNAL & CHILD HEALTH HOSPITAL
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411309000.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing detection of pathogenic mutations of POGZ genes relies on high-cost and long-term second-generation sequencing technology, which is difficult to meet the needs of rapid and economical diagnosis.

Method used

A primer combination and kit for detecting pathogenic mutations of POGZ genes are provided. Through Sanger sequencing or gel electrophoresis detection, multiple sets of primer groups are used to determine whether there are pathogenic mutations in POGZ genes, simplifying the detection process and reducing costs.

Benefits of technology

It realizes rapid detection of pathogenic mutations of POGZ gene, shortens the detection cycle, reduces the detection cost, and allows routine biological laboratories to conduct low-cost rapid screening.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118957055A_ABST
    Figure CN118957055A_ABST
Patent Text Reader

Abstract

The invention discloses a primer combination and a kit for detecting POGZ gene pathogenic mutation, and relates to the technical field of biology, the primer combination for detecting POGZ gene pathogenic mutation comprises a first primer group, a second primer group, a third primer group, a fourth primer group and a fifth primer group; according to the technical scheme provided by the invention, Sanger sequencing or gel electrophoresis detection can be utilized to complete the detection of the pathogenic mutation of the POGZ gene, that is, whether the pathogenic mutation exists in the POGZ gene or not can be determined through Sanger sequencing, so that the detection period is shortened, and the detection cost is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a primer combination and a kit for detecting pathogenic mutations of a POGZ gene. Background Art

[0002] Neurodevelopmental disorders (NDDs) are a complex group of diseases that cover a variety of neurodevelopmental abnormalities, ranging from intellectual disability (ID) to autism spectrum disorder (ASD). The etiology of these diseases is complex and they show significant phenotypic and genotypic heterogeneity, making diagnosis difficult. In recent years, advances in genomics technology have provided new avenues for revealing the genetic basis of NDDs, among which the study of the POGZ (Pogo transposable element with ZNF domain) gene has attracted widespread attention. The POGZ gene is located in the q21.3 region of chromosome 1, with a gene size of approximately 57 kb and a coding sequence of 4223 bp. The protein it encodes belongs to the zinc finger protein family and has multiple functional domains, such as the transposase domain at the C-terminus. The key role of POGZ protein in various cellular processes, such as cell cycle progression, chromosome segregation, and DNA repair, makes it of great significance in brain development and function. In recent years, mutations in the POGZ gene have been found to be closely associated with monogenic inherited neurodevelopmental disorders such as White-Sutton syndrome (WHSUS). WHSUS is a syndrome with diverse manifestations, and patients may experience intellectual disability, autism spectrum disorder, anxiety, sleep disorders, etc. Studies have found that loss-of-function mutations in the POGZ gene are the main cause of the syndrome, and the same POGZ mutation usually leads to similar clinical manifestations.

[0003] Currently, pathogenic mutations of the POGZ gene can only be detected through whole exome sequencing (WES) or whole genome sequencing (WES) technology. Both methods are second-generation sequencing technologies, which have high requirements for detection technology and equipment, are expensive, and have a long cycle. Summary of the invention

[0004] The main purpose of the present invention is to propose a primer combination and a kit for detecting pathogenic mutations in the POGZ gene, aiming to determine whether the POGZ gene has a pathogenic mutation by Sanger sequencing or gel electrophoresis detection, thereby shortening the detection cycle and reducing the detection cost.

[0005] To achieve the above object, the present invention proposes a primer set for detecting pathogenic mutations of POGZ gene, comprising a first primer set, a second primer set, a third primer set, a fourth primer set and a fifth primer set;

[0006] The first primer set includes a first upstream primer and a first downstream primer, the nucleotide sequence of the first upstream primer is shown in SEQ ID NO.1, and the nucleotide sequence of the first downstream primer is shown in SEQ ID NO.2;

[0007] The second primer set includes a second upstream primer and a second downstream primer, the nucleotide sequence of the second upstream primer is shown in SEQ ID NO.3, and the nucleotide sequence of the second downstream primer is shown in SEQ ID NO.4;

[0008] The third primer set includes a third upstream primer and a third downstream primer, the nucleotide sequence of the third upstream primer is shown in SEQ ID NO.5, and the nucleotide sequence of the third downstream primer is shown in SEQ ID NO.6;

[0009] The fourth primer set includes a fourth upstream primer and a fourth downstream primer, the nucleotide sequence of the third upstream primer is shown in SEQ ID NO.7, and the nucleotide sequence of the third downstream primer is shown in SEQ ID NO.8;

[0010] The fifth primer set includes a fifth upstream primer and a fifth downstream primer. The nucleotide sequence of the fifth upstream primer is shown in SEQ ID NO.9, and the nucleotide sequence of the fifth downstream primer is shown in SEQ ID NO.10.

[0011] Optionally / in one embodiment, the first primer set, the second primer set, the third primer set, and the fourth primer set are used for Sanger sequencing.

[0012] Optionally / in one embodiment, the PCR reaction system for Sanger sequencing includes the following components:

[0013] 10×PCR Buffer;

[0014] dNTPs (2.5 mM);

[0015] MgCl2 (25 mM);

[0016] Upstream primer;

[0017] Downstream primer;

[0018] Genomic DNA (100 ng / μL);

[0019] Taq DNA polymerase;

[0020] ddH2O.

[0021] Optionally / in one embodiment, the volumes of the components of the PCR reaction system for Sanger sequencing are as follows:

[0022] 10×PCR Buffer: 1.0 μL;

[0023] dNTP (2.5 mM): 0.8 μL;

[0024] MgCl2 (25 mM): 3.0 μL;

[0025] Upstream primer: 0.4 μL;

[0026] Downstream primer: 0.4 μL;

[0027] Genomic DNA (100 ng / μL): 1.0 μL;

[0028] Taq DNA polymerase: 0.1 μL;

[0029] ddH2O: 3.3 μL;

[0030] Total volume: 10 μL.

[0031] Optionally / in one embodiment, the fifth primer set is used for gel electrophoresis detection.

[0032] Optionally / in one embodiment, the reverse transcription system of the fifth primer set includes the following components: mRNA: 8.0 μL;

[0033] Nuclease-Free Water: 0.6μL;

[0034] 5×Reaction Buffer: 4.0μL;

[0035] MgCl2 (25 mM): 4.0 μL;

[0036] Oligo(dT)15Primer(500μ / mL): 0.5μL;

[0037] Random Primers (500μ / mL): 0.5μL;

[0038] PCR Nucleotide Mix: 1.0μL;

[0039] Recombinant Ribonuclease Inhibitor: 0.4μL;

[0040] Reverse Transcriptase: 1.0μL;

[0041] Total volume: 20 μL.

[0042] Optionally / in one embodiment, the PCR reaction system of the fifth primer set includes the following components: 10×PCRBuffer;

[0043] dNTPs (2.5 mM);

[0044] MgCl2 (25 mM);

[0045] Upstream primer;

[0046] Downstream primer;

[0047] Genomic DNA (100 ng / μL);

[0048] Taq DNA polymerase;

[0049] ddH2O.

[0050] Optionally / in one embodiment, the volumes of the components of the PCR reaction system of the fifth primer set are as follows:

[0051] 10×PCR Buffer: 1.0 μL;

[0052] dNTP (2.5 mM): 0.8 μL;

[0053] MgCl2 (25 mM): 3.0 μL;

[0054] Upstream primer: 0.4 μL;

[0055] Downstream primer: 0.4 μL;

[0056] cDNA: 1.0 μL;

[0057] Taq DNA polymerase: 0.1 μL;

[0058] ddH2O: 3.3 μL;

[0059] Total volume: 10 μL.

[0060] The present invention also provides a kit for detecting pathogenic mutations of the POGZ gene, comprising the above primer set

[0061] The present invention also proposes the use of the kit in detecting pathogenic mutations of the POGZ gene.

[0062] The technical solution of the present invention adopts multiple sets of primer groups to detect the pathogenic mutation of the POGZ gene, so that the detection of the pathogenic mutation of the POGZ gene can be completed by Sanger sequencing or gel electrophoresis detection, that is, it can be determined by Sanger sequencing whether the POGZ gene has a pathogenic mutation, thereby shortening the detection cycle and reducing the detection cost. BRIEF DESCRIPTION OF THE DRAWINGS

[0063] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the structures shown in these drawings without paying creative work.

[0064] Figure 1 This is a schematic diagram of the Sanger sequencing results of Example 1 of the present invention;

[0065] Figure 2 This is a schematic diagram of the Sanger sequencing results of Example 2;

[0066] Figure 3 This is a schematic diagram of the Sanger sequencing results of Example 3;

[0067] Figure 4 This is a schematic diagram of the Sanger sequencing results of Example 4;

[0068] Figure 5 Schematic diagram of gel electrophoresis detection in Example 4.

[0069] The realization of the purpose, functional features and advantages of the present invention will be further explained in conjunction with embodiments and with reference to the accompanying drawings. DETAILED DESCRIPTION

[0070] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0071] It should be noted that if the embodiments of the present invention involve directional indications (such as up, down, left, right, front, back, etc.), the directional indications are only used to explain the relative position relationship, movement status, etc. between the components in a certain specific posture. If the specific posture changes, the directional indication will also change accordingly.

[0072] In addition, if there are descriptions involving "first", "second", etc. in the embodiments of the present invention, the descriptions of "first", "second", etc. are only used for descriptive purposes and cannot be understood as indicating or implying their relative importance or implicitly indicating the number of technical features indicated. Therefore, the features limited to "first" and "second" may explicitly or implicitly include at least one of the features. In addition, if "and / or" or "and / or" appears in the full text, its meaning includes three parallel solutions. Taking "A and / or B" as an example, it includes solution A, solution B, or solutions that satisfy both A and B. In addition, the technical solutions between the various embodiments can be combined with each other, but it must be based on the ability of ordinary technicians in this field to implement. When the combination of technical solutions is contradictory or cannot be implemented, it should be deemed that such combination of technical solutions does not exist and is not within the scope of protection required by the present invention.

[0073] Neurodevelopmental disorders (NDDs) are a complex group of diseases that cover a variety of neurodevelopmental abnormalities, ranging from intellectual disability (ID) to autism spectrum disorder (ASD). The etiology of these diseases is complex and they show significant phenotypic and genotypic heterogeneity, making diagnosis difficult. In recent years, advances in genomics technology have provided new avenues for revealing the genetic basis of NDDs, among which the study of the POGZ (Pogo transposable element with ZNF domain) gene has attracted widespread attention. The POGZ gene is located in the q21.3 region of chromosome 1, with a gene size of approximately 57 kb and a coding sequence of 4223 bp. The protein it encodes belongs to the zinc finger protein family and has multiple functional domains, such as the transposase domain at the C-terminus. The key role of POGZ protein in various cellular processes, such as cell cycle progression, chromosome segregation, and DNA repair, makes it of great significance in brain development and function. In recent years, mutations in the POGZ gene have been found to be closely associated with monogenic inherited neurodevelopmental disorders such as White-Sutton syndrome (WHSUS). WHSUS is a syndrome with diverse manifestations, and patients may experience intellectual disability, autism spectrum disorder, anxiety, sleep disorders, etc. Studies have found that loss-of-function mutations in the POGZ gene are the main cause of the syndrome, and the same POGZ mutation usually leads to similar clinical manifestations.

[0074] Currently, pathogenic mutations of the POGZ gene can only be detected through whole exome sequencing (WES) or whole genome sequencing (WES) technology. Both methods are second-generation sequencing technologies, which have high requirements for detection technology and equipment, are expensive, and have a long cycle.

[0075] To solve the above problems, the present invention proposes a primer combination and a kit for detecting pathogenic mutations in the POGZ gene, aiming to determine whether the POGZ gene has a pathogenic mutation by relatively simple detection methods such as Sanger sequencing, thereby shortening the detection cycle and reducing the detection cost.

[0076] The present invention provides 5 sets of primers, which are respectively used to detect 4 POGZ gene pathogenic mutations found in clinical practice. Only conventional Sanger sequencing or PCR product gel electrophoresis is required to achieve the detection purpose. The technical requirements are very low, and the simplest biological laboratory has the detection conditions. The test results can be obtained quickly and the cost is low.

[0077] Specifically, the present invention proposes a primer set for detecting pathogenic mutations of the POGZ gene, comprising a first primer set, a second primer set, a third primer set, a fourth primer set and a fifth primer set;

[0078] The first primer set includes a first upstream primer and a first downstream primer, the nucleotide sequence of the first upstream primer is shown in SEQ ID NO.1, and the nucleotide sequence of the first downstream primer is shown in SEQ ID NO.2;

[0079] The second primer set includes a second upstream primer and a second downstream primer, the nucleotide sequence of the second upstream primer is shown in SEQ ID NO.3, and the nucleotide sequence of the second downstream primer is shown in SEQ ID NO.4;

[0080] The third primer set includes a third upstream primer and a third downstream primer, the nucleotide sequence of the third upstream primer is shown in SEQ ID NO.5, and the nucleotide sequence of the third downstream primer is shown in SEQ ID NO.6;

[0081] The fourth primer set includes a fourth upstream primer and a fourth downstream primer, the nucleotide sequence of the third upstream primer is shown in SEQ ID NO.7, and the nucleotide sequence of the third downstream primer is shown in SEQ ID NO.8;

[0082] The fifth primer set includes a fifth upstream primer and a fifth downstream primer. The nucleotide sequence of the fifth upstream primer is shown in SEQ ID NO.9, and the nucleotide sequence of the fifth downstream primer is shown in SEQ ID NO.10.

[0083] The inventors conducted genetic studies on a large number of NDD patient families and found that four families were caused by POGZ gene mutations. These four different mutations were all loss of function (LOF) mutations.

[0084] It should be noted that the wild-type POGZ gene is coded as ENSG00000143442 in the Ensemble database (https: / / useast.ensembl.org / index.html). Since there are hundreds of genes that can cause NDD, in order to determine which gene mutation is causing the patient, genetic etiology testing is generally performed through whole exome sequencing (WES) or whole genome sequencing (WES) technology. Both methods are second-generation sequencing technologies, which are expensive and have a long cycle. Therefore, it is necessary to develop rapid and economical detection methods for pathogenic mutations discovered clinically.

[0085] In addition, generally speaking, pathogenic mutations in the POGZ gene lead to White-Sutton syndrome in a dominant inheritance pattern, but NDD-type diseases often have incomplete penetrance, that is, different individuals carrying the same pathogenic mutations may suffer from the disease while others may live normally. Therefore, the present invention is only used to detect whether there are these four pathogenic mutations, and is not used as a diagnostic purpose for whether White-Sutton syndrome is present. The diagnosis of the disease requires a more extensive clinical evaluation.

[0086] In the present invention, the normal human POGZ gene coding sequence (cDNA) is shown as SEQ ID NO.11, the normal human POGZ protein amino acid sequence is shown as SEQ ID NO.12, and the alignment information of the four mutations with the human genome reference sequence GRCh37 is as follows:

[0087] 1. The base T at the physical position 151403180 on chromosome 1 is deleted, that is, the c.421delT frameshift mutation, and the amino acid change is p.(Ser141Profs*17), that is, the serine at position 141 is changed to proline, and a new stop codon is generated after the frameshift of 17 amino acids, and only a loss-of-function truncated protein with premature termination can be synthesized. The amino acid sequence of the POGZ protein of the c.421delT pathogenic mutation (p.Ser141Profs*17) is shown in SEQ ID NO.13.

[0088] 2. A four-base CCTG deletion at the physical position 151380943-151380940 on chromosome 1, i.e., the c.2176_2179del mutation, occurs. The amino acid change is p.(Pro726Serfs*19), i.e., the proline at position 726 is changed to serine, and a new stop codon is generated after the frameshift of 19 amino acids. Only a prematurely terminated loss-of-function truncated protein can be synthesized. The amino acid sequence of the POGZ protein of the c.2176_2179del pathogenic mutation (p.Pro726Serfs*19) is shown in SEQ ID NO.14.

[0089] The base C at the physical position 151380601 of chromosome 3.1 changes to T, that is, the c.2350C>T mutation, and the amino acid changes to p.(Arg784*), that is, the arginine at position 784 is directly changed to a stop codon (the codon CGA changes to TGA), and only a prematurely terminated loss-of-function truncated protein can be synthesized. The amino acid sequence of the POGZ protein with the c.2350C>T pathogenic mutation (p.Arg784*) is shown in SEQ ID NO.15.

[0090] 4. The base A at the physical position 151379501 ​​on chromosome 1 changes to G, that is, the c.2433-2A>G mutation. Because this mutation destroys the splicing site, the entire 17th exon 113bp of the POGZ gene is missing in the mature mRNA. The amino acid changes to p.(Ser811Argfs*15), that is, the serine at position 811 becomes arginine, and a new stop codon is generated after the frameshift of 15 amino acids, so only a prematurely terminated loss-of-function truncated protein can be synthesized. The amino acid sequence of the POGZ protein with the c.2433-2A>G pathogenic mutation (p.Ser811Argfs*15) is shown in SEQ ID NO.16.

[0091] In the present invention, the corresponding relationship between the above four mutations and each primer set and the primer sequence in each primer set are shown in the following table:

[0092] Table 1 Primer sequences and corresponding mutations in the primer set

[0093]

[0094] It should be noted that, in the present invention, the first to fourth primer sets are all used for Sanger sequencing, and the fifth primer set is used for gel electrophoresis detection.

[0095] Among the five primer sets provided in the present invention, the specific process for the first primer set to the fourth primer set in Sanger sequencing is as follows:

[0096] 1. Draw peripheral blood from the subject in an EDTA anticoagulant tube and extract genomic DNA;

[0097] 2. Prepare the PCR reaction system. The PCR reaction system is shown in the following table:

[0098] Table 2 Sanger sequencing PCR reaction system

[0099]

[0100]

[0101] 3. Perform PCR amplification in a thermal cycler under the following conditions. The amplification program is shown in the following table:

[0102] Table 3 PCR amplification program

[0103] Temperature(℃) time Number of cycles 95 4 minutes 1 95 30 seconds 32 60 15 seconds 32 72 30 seconds 32 72 1 minute 1 4 ∞ 1

[0104] The PCR product is directly subjected to conventional Sanger sequencing. The sequencing primers are the same as the PCR primers, and the result can be directly judged based on the sequencing results.

[0105] The sizes of the amplified products of the first to fourth primer sets are as follows:

[0106] Table 4 Size of amplified products of each primer set

[0107]

[0108]

[0109] Among the five primer sets provided in the present invention, the fifth primer set can detect exon 17 splicing mutations. The specific process for the fifth primer set in gel electrophoresis detection is as follows:

[0110] 1. Draw peripheral blood from the subject in an EDTA anticoagulant tube and extract mRNA;

[0111] 2. Prepare the reverse transcription system as follows:

[0112] Table 5 Reverse transcription system

[0113] Components Volume (μL) mRNA 8.0 Nuclease-Free Water 0.6 5×Reaction Buffer 4.0 <![CDATA[MgCl2(25mM)]]> 4.0 <![CDATA[Oligo(dT) 15 Primer(500μ / mL)]]> 0.5 Random Primers (500μ / mL) 0.5 PCR Nucleotide Mix 1.0 Recombinant Ribonuclease Inhibitor 0.4 Reverse Transcriptase 1.0 Total volume 20

[0114] 3. The reverse transcription thermal cycle conditions were: 42°C, 15 min extension to synthesize cDNA, 70°C, 15 min reverse transcriptase quenching;

[0115] 4. Using the cDNA synthesized in the previous step as a template, the fifth primer set was used to configure the PCR reaction system. The specific reaction system is shown in the following table:

[0116] Table 6 PCR reaction system of the fifth primer set

[0117]

[0118]

[0119] 5. Perform PCR amplification in a thermal cycler under the following conditions. The amplification program is shown in the following table:

[0120] Table 7 PCR amplification program of the fifth primer set

[0121] Temperature(℃) time Number of cycles 95 4 minutes 1 95 30 seconds 32 60 15 seconds 32 72 30 seconds 32 72 1 minute 1 4 ∞ 1

[0122] The amplified product was subjected to gel electrophoresis and the size of the bands could be used to determine whether the product was 464 bp or a normal POGZ gene. If a 351 bp product was also produced, it indicated that the entire exon 17 was skipped due to a splicing site mutation.

[0123] The following is described in conjunction with specific embodiments:

[0124] Example 1

[0125] Example 1 is a 15-year-old boy who was clinically diagnosed with moderate intellectual disability (ID). The characteristic phenotype is language development and language expression problems. In addition, his right ear has a slight ear deformity (this is a common clinical phenotype of WHSUS). The five primer sets provided by the present invention were used for detection, and the POGZ gene was detected to have a c.421delT frameshift pathogenic mutation. The results are as follows: Figure 1 shown.

[0126] Example 2

[0127] Example 2 is a 10-year-old girl, the only child of a healthy pair of non-consanguineous parents. Clinically, the girl showed mild intellectual disability and delayed language development. The five primer sets provided by the present invention were used for detection, and the POGZ gene was detected to have a c.2176_2179del deletion pathogenic mutation. The results are as follows: Figure 2 shown.

[0128] Example 3

[0129] Example 3 is the third daughter of a non-consanguineous couple. She was clinically diagnosed with delayed language development at the age of 10. Her learning ability, especially reading and calculation ability, is poor. In addition, she also has problems with motor coordination. The five primer sets provided by the present invention were used for detection, and the POGZ gene was detected to have a c.2350C>T pathogenic mutation. The results are as follows: Figure 3 shown.

[0130] Example 4

[0131] Example 4 is an 8-year-old boy who exhibits severe intellectual disability and delayed language and motor development. He began to walk at the age of two and exhibited poor gross motor skills. Language development was significantly delayed, and he could not speak monosyllabic words until the age of three and began to speak simple sentences at the age of five. He was unable to perform basic calculations or read, and exhibited a repetitive language pattern. In addition, his face exhibited strabismus and epicanthus. He also has a fraternal twin brother, but the phenotype is normal. Using the five primer sets provided in the present invention for testing, it was detected that his POGZ gene carried the c.2433-2A>G pathogenic mutation, and the results are as follows: Figure 4 and Figure 5 shown.

[0132] refer to Figure 4 and Figure 5 It should be noted that, after verification by Sanger sequencing, 113 bp of exon 17 was completely missing in the mature mRNA. Figure 5 The 351bp band in the middle is very light; the reason is that the deletion of 113bp leads to a frameshift mutation, thereby generating a non-functional truncated protein, and the nonsense-mediated mRNA degradation (NMD) mechanism in the cell causes the mutant mRNA to be selectively degraded, which in turn causes the 351bp amplification band corresponding to the mutant gene to be very light.

[0133] The present invention also proposes a kit for detecting pathogenic mutations of the POGZ gene, the kit comprising the above-mentioned primer set. The specific sequence and usage of the primer set refer to the above description and embodiments. Since the present kit adopts all the technical solutions of all the above-mentioned embodiments, it has at least all the beneficial effects brought by the technical solutions of the above-mentioned embodiments, which will not be described one by one here.

[0134] The present invention also proposes the use of the above-mentioned kit in detecting pathogenic mutations of the POGZ gene. The above-mentioned kit can be used as one of the means for rapid screening of pathogenic mutations of the POGZ gene; and because the present invention uses Sanger sequencing and gel electrophoresis detection, the experimental conditions are very low and can be used in conventional biological laboratories, and the cost is very low and the detection cycle is short.

[0135] The above description is only an exemplary embodiment of the present invention, and does not limit the patent scope of the present invention. All equivalent structural changes made by using the contents of the present invention specification and drawings under the technical concept of the present invention, or directly / indirectly applied in other related technical fields are included in the patent protection scope of the present invention.

Claims

1. A primer set for detecting pathogenic mutations in the POGZ gene, characterized in that: Comprising a first primer set, a second primer set, a third primer set, a fourth primer set and a fifth primer set; The first primer set includes a first upstream primer and a first downstream primer, the nucleotide sequence of the first upstream primer is shown in SEQ ID NO.1, and the nucleotide sequence of the first downstream primer is shown in SEQ ID NO.2; The second primer set includes a second upstream primer and a second downstream primer, the nucleotide sequence of the second upstream primer is shown in SEQ ID NO.3, and the nucleotide sequence of the second downstream primer is shown in SEQ ID NO.4; The third primer set includes a third upstream primer and a third downstream primer, the nucleotide sequence of the third upstream primer is shown in SEQ ID NO.5, and the nucleotide sequence of the third downstream primer is shown in SEQ ID NO.6; The fourth primer set includes a fourth upstream primer and a fourth downstream primer, the nucleotide sequence of the third upstream primer is shown in SEQ ID NO.7, and the nucleotide sequence of the third downstream primer is shown in SEQ ID NO.8; The fifth primer set includes a fifth upstream primer and a fifth downstream primer. The nucleotide sequence of the fifth upstream primer is shown in SEQ ID NO.9, and the nucleotide sequence of the fifth downstream primer is shown in SEQ ID NO.

10.

2. The primer set according to claim 1, characterized in that The first primer set, the second primer set, the third primer set, and the fourth primer set are used for Sanger sequencing.

3. The primer set according to claim 2, characterized in that The PCR reaction system of the Sanger sequencing includes the following components: 10×PCR Buffer; dNTPs (2.5 mM); MgCl2 (25 mM); Upstream primer; Downstream primer; Genomic DNA (100 ng / μL); Taq DNA polymerase; ddH2O.

4. The primer set according to claim 3, characterized in that The volumes of the components of the PCR reaction system for Sanger sequencing are as follows: 10×PCR Buffer: 1.0 μL; dNTP (2.5 mM): 0.8 μL; MgCl2 (25 mM): 3.0 μL; Upstream primer: 0.4 μL; Downstream primer: 0.4 μL; Genomic DNA (100 ng / μL): 1.0 μL; Taq DNA polymerase: 0.1 μL; ddH2O: 3.3 μL; Total volume: 10 μL.

5. The primer set according to claim 1, characterized in that The fifth primer set is used for gel electrophoresis detection.

6. The primer set according to claim 5, characterized in that The reverse transcription system of the fifth primer set includes the following components: mRNA: 8.0 μL; Nuclease-Free Water: 0.6μL; 5×Reaction Buffer: 4.0μL; MgCl2 (25 mM): 4.0 μL; Oligo(dT) 15 Primer(500μ / mL):0.5μL; Random Primers (500μ / mL): 0.5μL; PCR Nucleotide Mix: 1.0μL; Recombinant Ribonuclease Inhibitor: 0.4μL; Reverse Transcriptase: 1.0μL; Total volume: 20 μL.

7. The primer set according to claim 6, characterized in that The PCR reaction system of the fifth primer set includes the following components: 10×PCR Buffer; dNTPs (2.5 mM); MgCl2 (25 mM); Upstream primer; Downstream primer; Genomic DNA (100 ng / μL); Taq DNA polymerase; ddH2O.

8. The primer set according to claim 7, characterized in that The volumes of the components of the PCR reaction system of the fifth primer set are as follows: 10×PCR Buffer: 1.0 μL; dNTP (2.5 mM): 0.8 μL; MgCl2 (25 mM): 3.0 μL; Upstream primer: 0.4 μL; Downstream primer: 0.4 μL; cDNA: 1.0 μL; Taq DNA polymerase: 0.1 μL; ddH2O: 3.3 μL; Total volume: 10 μL.

9. A kit for detecting pathogenic mutations in the POGZ gene, characterized in that: Comprising the primer set according to any one of claims 1 to 9.

10. Use of the kit according to claim 9 in detecting pathogenic mutations of the POGZ gene.

Citation Information

Patent Citations

  • Whole-chromosome genotyping chip for synchronously detecting multiple birth defect genetic diseases and method and application of whole-chromosome genotyping chip

    CN114196736A

  • Genetic optic neuropathy detection kit for synchronously detecting nuclear gene and mitochondrial gene defects and application thereof

    CN116676382A

  • Use and production of CHD8+ / - transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder

    US20180044662A1